Notably, cirmtuzumab, an anti-ROR1 mAb, reached phase I clinical trial in patients with relapsed chronic lymphocytic leukemia (LCC) [95]. The gene discussed is ROR1; the disease is B-cell chronic lymphocytic leukemia.